To The Moon

$Merck(MRK)$

$Merck & Co., Inc.(MRK) +2.39% Closes at $152.55: mRNA Cancer Vaccine Breakthrough Fuels All-Time High, $154.49 Resistance in Sight 🚀

Latest Close Data: MRK closed at $152.55 (+2.39%) on Aug 24, 2026, just 1.3% below its 52-week high of $154.49. Pre-market had indicated $148.70, while after-hours extended to $154.14, suggesting continued momentum into the next session.

Core Market Drivers: Merck and Moderna's personalized mRNA cancer vaccine intismeran autogene + Keytruda achieved a historic Phase III success in INTerpath-001, hitting the primary RFS endpoint — the first positive Phase III result for an individualized mRNA cancer vaccine. Morgan Stanley upgraded MRK from Equalweight to Overweight, lifting its price target from $116 to $179. RBC cautioned valuation is at historical highs.

Technical Analysis: 📊 MACD remains firmly bullish with DIF at 5.52 vs DEA at 3.42, histogram expanding to +4.20 — momentum accelerating. RSI(6) at 83.15 signals overbought conditions; RSI(12) at 79.29 and RSI(24) at 72.16 confirm strong but extended bullish pressure. KDJ shows K=87.25, D=82.86, J=96.03 — near overbought zone. Volume of 15.98M shares (volume ratio 1.07) supports the breakout.

Key Price Levels: 🎯 Primary support: $148.59 (today's low / 5-day pivot). Strong resistance: $154.49 (52-week high, now under test). Immediate pivot: $153.07 (prior resistance, now breakout confirmation level).

Valuation Perspective: P/E TTM stands at 119.85 — extremely stretched versus historical averages. Forward P/E of 55.55 sits well above the +1 Std.Dev band of 44.94, indicating the market is pricing in substantial pipeline upside. P/S TTM at 5.65, P/B at 8.98, and dividend yield at 2.18%.

Analyst Targets: 28 institutions cover MRK with mean target of $144.88 (range $95–$186). Ratings: 7 Strong Buy, 16 Buy, 9 Hold. Current price exceeds the mean target by ~5%, suggesting analysts may need to revise upward following the vaccine readout.

Weekly Outlook: 📅 Expect consolidation between $148.5–$155.0 as the stock digests overbought RSI. A decisive close above $154.49 opens path toward $160–$165 psychological zone. Failure to hold $148.59 could trigger mean reversion toward $143–$145 (20-day EMA area).

⚠️ Risk Disclaimer: This technical analysis is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results. Trading involves substantial risk of loss. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions.

🎯 $Merck & Co., Inc.(MRK) Options Strategy: Bull Call Spread

• Underlying: MRK (Merck & Co., Inc.)

• View: Cautiously bullish / momentum continuation after mRNA vaccine breakthrough; overbought RSI suggests limited near-term upside without consolidation

• Strategy Type: Debit spread (defined risk, directional long)

• Option Contract Portfolio:

  • Buy 1x MRK 2026-09-18 150 Call @ $4.02 (mid)

  • Sell 1x MRK 2026-09-18 160 Call @ $0.46 (mid)

  • Net Debit: $3.56 per spread

• Max Gain & Loss:

  • Max Gain: ($160 – $150 – $3.56) × 100 = $644 per spread

  • Max Loss: $356 per spread (net debit paid)

• Initial Cost/Credit: $3.56 Debit

🐯🪙 Share your choice and reasoning in the comments — thoughtful views may receive Tiger Coins!

Good allocation isn’t just about investing — it’s also about keeping everyday life organised.

Just like a well-balanced portfolio, the right organisation can make business trips, travel and workouts a little easier. The new Tiger Toiletry Bag features a dual-layer dry & wet separation design with plenty of space to keep your essentials neatly organised, wherever you go.

Redeem the new Tiger Toiletry Bag now in Tiger Coin Mall. https://laohu8.com/J/redeemGift?goodID=100538&type=delivery